The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre

• Published in: Amyloid 2022-10, Vol.29 (4), p.237-244
• Main Authors: Cohen, Oliver C., Blakeney, Iona J., Law, Steven, Ravichandran, Sriram, Gilbertson, Janet, Rowczenio, Dorota, Mahmood, Shameem, Sachchithanantham, Sajitha, Wisniowski, Brendan, Lachmann, Helen J., Whelan, Carol J., Martinez-Naharro, Ana, Fontana, Marianna, Hawkins, Philip N., Gillmore, Julian D., Wechalekar, Ashutosh D.
• Format: Article
• Language: English
• Subjects: Adult; Amyloid; amyloidosis; Amyloidosis - diagnosis; Amyloidosis, Familial - diagnosis; Amyloidosis, Familial - genetics; Amyloidosis, Familial - surgery; APOA1; Apolipoprotein A-I - genetics; Apolipoprotein A-I - metabolism; Apolipoprotein AI; Humans; Kidney - metabolism; survival; transplantation; United Kingdom
• ISSN: 1350-6129; 1744-2818
• DOI: 10.1080/13506129.2022.2070741

Hereditary apolipoprotein A-I (AApoAI) amyloidosis is a rare heterogeneous disease with variable age of onset and organ involvement. There are few series detailing the natural history and outcomes of solid organ transplantation across a range of causative APOA1 gene mutations. We identified all patients with AApoAI amyloidosis who presented to the National Amyloidosis Centre (NAC) between 1986 and 2019. In total, 57 patients with 14 different APOA1 mutations were identified including 18 patients who underwent renal transplantation (5 combined liver-kidney (LKT) and 2 combined heart-kidney (HKT) transplants). Median age of presentation was 43 years and median time from presentation to referral was 3 (0-31 years). Involvement of the kidneys, liver and heart by amyloid was detected in 81%, 67% and 28% of patients, respectively. Renal amyloidosis was universal in association with the most commonly identified variant (Gly26Arg, n = 28). Across all variants, patients with renal amyloidosis had a median creatinine of 159 µmol/L and median urinary protein of 0.3 g/24 h at the time of diagnosis of AApoAI amyloidosis and median time from diagnosis to end-stage renal disease was 15.0 (95% CI: 10.0-20.0) years. Post-renal transplantation, median allograft survival was 22.0 (13.0-31.0) years. There was one early death following transplantation (infection-related at 2 months post-renal transplant) and no episodes of early rejection leading to graft failure. Liver transplantation led to regression of amyloid in all four cases in whom serial 123 I-SAP scintigraphy was performed. AApoAI amyloidosis is a slowly progressive disease that is challenging to diagnose. The outcomes of transplantation are encouraging and graft survival is excellent.